Join the 'Noonan's Syndrome' group to help and get support from people like you. How it works
Noonan's Syndrome Blog
| Tweet |
Novo Nordisk Receives FDA Approval for Norditropin FlexPro for Growth Hormone Treatment
Posted 10 Mar 2010 by Drugs.com
PRINCETON, N.J., March 3, 2010 /PRNewswire/ – Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Norditropin FlexPro (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter. Norditropin FlexPro has a user friendly design which makes it easy to learn and use, and an audible click that confirms that the medication has left the pen. Norditropin FlexPro requires no reconstitution and no loading of cartridges. Norditropin FlexPro is available in 5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL pens. After first use, the 5 mg/1.5 mL and 10 mg/1.5 mL pens may be left at room temperature for up to three weeks without risk of spoilage. In a study designed to evaluate the usability of the product, 100 percent of patients found it easy to learn ... Read more
Related support groups: Adult Human Growth Hormone Deficiency, Pediatric Growth Hormone Deficiency, Somatropin, Norditropin, Turner's Syndrome, Norditropin Nordiflex, Noonan's Syndrome